

**FOLEY LARDNER**

ATTORNEYS AT LAW

WASHINGTON HARBOUR  
3000 K STREET, N.W., SUITE 500  
WASHINGTON, D.C. 20007-5143  
TELEPHONE: 202.672.5300  
FACSIMILE: 202.672.5399  
WWW.FOLEYLARDNER.COM

**FACSIMILE TRANSMISSION**Total # of Pages 21 (including this page)

TO:	PHONE #:	FAX #:
Examiner Schwadren USPTO	703-308-4680	703-746-5339

From : Jayme A. Huleatt  
Email Address : jhuleatt@foleylaw.com  
Sender's Direct Dial : 202.672.5542  
Date : December 24, 2002  
Client/Matter No : 018733-0996  
User ID No : 0409

**MESSAGE:**


USN 09/741,843

ATTACHED FOR FILING ARE THE FOLLOWING DOCUMENTS:

1. Amendment Transmittal
2. Third Preliminary Amendment

I hereby certify that these papers are being facsimile transmitted to Examiner Schwadren, at USPTO, on this date.

December 24, 2002

  
Amy D. Mason  
Secretary for Jayme A. Huleatt

If there are any problems with this transmission or if you have not received all of the pages, please call 202.672.5340.

Operator:	Time Sent:	Return Original To: Amy D. Mason
-----------	------------	-------------------------------------

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Atty. Dkt. No. 018733-0996

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Shui-on LEUNG et al.

Title: IMMUNOCONJUGATES AND  
HUMANIZED ANTIBODIES  
SPECIFIC FOR B-CELL  
LYMPHOMA AND LEUKEMIA  
CELLS

Appl. No.: 09/741,843

Filing Date: 12/22/2000

Examiner: Ronald B. Schwadron

Art Unit: 1644

**AMENDMENT TRANSMITTAL**Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- ☐ Small Entity statement is enclosed.
- ☒ The fee required for additional claims is calculated below:

	Claims as Amended		Previously Paid For		Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	51	-	20	=	31	x	\$18.00	=	\$558.00
Independents:	6	-	3	=	3	x	\$84.00	=	\$252.00
First presentation of any Multiple Dependent Claims:						+	\$280.00	=	\$0.00
CLAIMS FEE TOTAL:									\$810.00

- ☐ Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

Atty. Dkt. No. 018733-0996

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$400.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$920.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,440.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,960.00	\$0.00
EXTENSION FEE TOTAL:			\$0.00
CLAIMS AND EXTENSION FEE TOTAL:			\$810.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract 1/2 of above):		\$0.00
TOTAL FEE:			\$810.00

- ☒ Please charge Deposit Account No. 19-0741 in the amount of \$810.00. A duplicate copy of this transmittal is enclosed.
- ☐ A check in the amount of \$810.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date December 24, 2002

By Stephen B. Maebius #46,785

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

*for* Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

*Officer*  
*MS*  
*12/24/2002*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Attorney Docket No. 18733/996**

In re patent application of

Shui-on LEUNG et al.

Serial No. 09/741,843

Filed: December 22, 2000

Group Art Unit: 1644

Examiner: R. Schwadron

For: IMMUNOCONJUGATES AND HUMANIZED ANTIBODIES  
SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS

**THIRD PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application on the merits, Applicants respectfully request the amendment of the application as follows:

**IN THE CLAIMS:**

Kindly cancel claims 25-43 without prejudice or disclaimer and add the following claims:

44. (New) An isolated polynucleotide encoding the amino acid sequence of a light chain variable region of an LL2 monoclonal antibody (mAb) or antigen binding fragment thereof comprising at least one complementarity-determining region (CDR) of the light chain of a murine LL2 (mLL2) mAb, wherein CDR1 comprises amino acids 24 to 40 of SEQ ID NO: 2, CDR2 comprises amino acids 56 to 62 of SEQ ID NO: 2 or CDR3 comprises 95 to 102 of SEQ ID NO: 2, wherein the LL2 mAb or antigen-binding fragment thereof retains the immunoreactivity of the mLL2.

45. (New) The isolated polynucleotide of claim 44, wherein said amino acid sequence encoding said light chain variable region further comprises framework regions (FRs) of a light chain variable region of atne or more human antibody.

46. (New) The isolated polynucleotide of claim 45, wherein said FRs comprise at least one amino acid substitution.